As cancer cells often characterized by abnormalities in the DNA repair mechanism, drug development based on synthetic lethality aimed at other remaining DNA repair mechanisms, for example, poly (ADP‐ribose) polymerase inhibitors for treating BRCA1/2‐mutated ovarian cancers, is clinically prominent [4, 8, 9]. The gene discussed is BRCA1; the disease is cancer.